Press Releases

August 11, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage

PDF Version
August 10, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School ; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1

PDF Version
August 6, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

Nationally recognized leader in corporate life sciences transactions SAN DIEGO , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease

PDF Version
August 4, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
July 31, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO , July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 29, 2020 at 12:30 AM EDT

Summary Toggle Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

SAN DIEGO , July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 28, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO , July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
July 23, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO , July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage

PDF Version
July 21, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Human dosing of LUNAR-COV19 expected soon Anti-Spike Glucoproteins Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration SAN

PDF Version 192.1 KB
July 1, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO , July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics

PDF Version